Rainer Metternich has been named Head of Small Molecules Research (SMR), Roche, effective immediately. He takes over from Klaus Strein, who will retire. SMR is a key part of Roche”s Pharma Research and Early Development (pRED) organization.
Metternich will lead some 800 scientists across Europe and the US who work in Medicinal Chemistry, Discovery Technologies, Process Research and Formulation and will oversee the development of SMR”s mid- and long-term vision and strategy and guide the group as it applies novel technologies to develop world-class compounds.
Dr. Rainer Metterhnich has worked for Novartis (formerly Sandoz), Schering AG, and Merck & Co. Since 2010, he has been the Chief Scientific Officer and Chief Business Officer with Caprotec Inc., a biotechnology company in Berlin, Germany, with expertise in chemical proteomics.
Rainer Metternich holds a PhD in Organic Chemistry from Philipps University, Marburg, Germany, and completed his Postdoctoral Fellowship in the Department of Chemistry at Harvard University. Well-known and respected in the chemistry community, he is also affiliated with several leading professional journals like Angewandte Chemie International Edition and has authored more than 30 publications.
- Roche, Basel, Switzerland